Advertisement

TAK

Takeda Pharmaceutical Company Limited

Healthcare · USD

Set alert

Price alert · TAK

All alert types
20.91 USD +0.90 +4.50%
As of Oct 30, 2026 Extended hours 20.91 0.00%
Bid
20.90 × 6,400
Ask
21.00 × 8,800
20.80 Day range 21.22
13.23 52-week range 20.91
YTD
+34.12%
1 year
+58.05%
Open
21.00
Prev close
20.01
Mkt cap
66.81B
Vol
4.62M
Avg vol
2.73M
EPS
0.07
P/E
298.71
Div yield
3.08%
More statistics
Low
20.80
High
21.22
Forward P/E
39.48
Beta
0.10
Short ratio
1.21
Inst. own
3.32%
Dividend
0.62
Ex-div date
Mar 30, 2026
Earnings
Jan 28, 2027
50-d avg
18.78
200-d avg
17.53
1y target
23.08

5D chart

Chart tools
Interval
TAK five-day price chart19.519.920.420.821.2Oct 26Oct 27Oct 28Oct 29Oct 30

Key statistics

Market cap
66.85B
Enterprise value
5.14T
Trailing P/E
298.93
Forward P/E
39.48
PEG ratio
0.45
Price / sales
0.01
Price / book
1.38
EPS (TTM)
0.07
Beta
0.10
Dividend yield
3.08%
Payout ratio
426.53%
Profit margin
-3.54%
Revenue (TTM)
4.62T
Revenue growth
10.20%
Free cash flow
541.44B
Total cash
460.98B
Total debt
5.54T
Return on equity
-2.26%
Shares outstanding
3.19B
Short % of float
0.10%
50-day average
18.78
200-day average
17.53

Analyst view

Consensus: strong buy

Strong buy
Price target (mean) 23.08 +10.4% upside
Target (low)
21.04
Target (mean)
23.08
Target (high)
26.06
Ratings (0m) 3 3 buy · 0 hold · 0 sell
  • Strong buy0
  • Buy3
  • Hold0
  • Sell0
  • Strong sell0

Next earnings

Jan 28, 2027

Expected Jan 28, 2027. Consensus EPS estimate 0.00.

Earnings history

Financials — quick view

All financials
TAK Revenue — quarterly 1.19T
2023-Q3 20222023-Q4 20232024-Q1 20232024-Q2 20232024-Q3 20232024-Q4 20242025-Q1 20242025-Q2 20242025-Q3 20242025-Q4 20252026-Q1 20252026-Q2 20252026-Q3 20252026-Q4 20262027-Q1 20262027-Q2 2026
TAK Net income — quarterly 192.46B
2023-Q3 20222023-Q4 20232024-Q1 20232024-Q2 20232024-Q3 20232024-Q4 20242025-Q1 20242025-Q2 20242025-Q3 20242025-Q4 20252026-Q1 20252026-Q2 20252026-Q3 20252026-Q4 20262027-Q1 20262027-Q2 2026
TAK EPS — quarterly 60.44
2023-Q3 20222023-Q4 20232024-Q1 20232024-Q2 20232024-Q3 20232024-Q4 20242025-Q1 20242025-Q2 20242025-Q3 20242025-Q4 20252026-Q1 20252026-Q2 20252026-Q3 20252026-Q4 20262027-Q1 20262027-Q2 2026

Earnings

TAK recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Jan 28, 2027Dec 30, 20260.2815———
Oct 29, 2026Sep 30, 20260.1450.3852+0.24+165.66%
Jul 30, 2026Jun 30, 20260.16890.225+0.06+33.21%
May 13, 2026Mar 31, 20260.21-0.04919-0.26-123.42%
Jan 29, 2026Dec 31, 20250.550.2131-0.34-61.25%
Oct 30, 2025Sep 30, 20250.44-0.02493-0.46-105.67%

Upgrades / downgrades

TAK analyst upgrades and downgrades
DateFirmActionFromTo
May 16, 2023TD CowenmainOutperformOutperform
Apr 4, 2023TD Cowenmain—Outperform
Mar 16, 2023B of A SecuritiesupNeutralBuy
Jul 19, 2022Cowen & Co.upMarket PerformOutperform
Oct 7, 2021Morgan StanleydownOverweightEqual-Weight
Mar 11, 2020JP Morganmain—Overweight

About Takeda Pharmaceutical Company Limited

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma-derived therapies, oncology, vaccines, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Takhzyro, Advate, Elaprase, Replagal, Vpriv, Adynovate/Adynovi, Livtencity, ADZYNMA, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Flexbumin, Adcetris, Leuplin/Enantone, Ninlaro, Iclusig, FRUZAQLA, Alunbrig, vyvanse/elvanse, Trintellix, and QDENGA brands. It has licensing and collaboration for the development and commercialization of products with Arrowhead Pharmaceuticals, Cour Pharmaceuticals, Engitix, Halozyme, Mirum Pharmaceuticals, Ucsd/Fortis Advisors, Zedira/Dr. Falk Pharma, Ac Immune, Acurastem, Anima Biotech, Biomarin, Denali Therapeutics, Luxna Biotech, Neurocrine Biosciences, Peptidream, Abbvie, Adimab, Ascentage Pharma, Crescendo Biologics, Exelixis, F-Star, Gsk, Heidelberg Pharma, Innovent Biologics, Keros Therapeutics, Kumquat Biosciences, Protagonist Therapeutics, Halozyme, Kamada, Johnson & Johnson/Momenta Pharmaceuticals, Previpharma, Novavax, Bridgene Biosciences, Charles River Laboratories, Iambic Therapeutics, Ipsen, Km Biologics, Massachusetts Institute Of Technology, and Nabla Bio. The company operates in Japan, the United States. Europe, Canada, Latin America, China, Asia, Russia/Commonwealth of Independent States, the Middle East, Oceania, and Africa. The company was founded in 1781 and is headquartered in Chuo, Japan.

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Country
Japan
Website
takeda.com

News

Your note

Sign in to keep a note on TAK — it syncs with the Stock Master app.

Institution ownership

TAK institution ownership
Holder% heldSharesValueReported
Capital Research Global Investors0.60%19,297,680403.80MJun 29, 2026
FMR, LLC0.30%9,599,302200.87MJun 29, 2026
Morgan Stanley0.22%6,994,924146.37MJun 29, 2026
Adage Capital Partners GP L.L.C.0.19%6,050,771126.61MJun 29, 2026
Goldman Sachs Group Inc0.16%5,125,032107.24MJun 29, 2026
Brandes Investment Partners L.P.0.14%4,539,34794.99MJun 29, 2026

Fund ownership

TAK fund ownership
Holder% heldSharesValueReported
AMERICAN MUTUAL FUND0.57%18,157,900379.95MSep 29, 2026
Capital Income Builder0.23%7,343,700153.67MSep 29, 2026
VanEck ETF Trust-VanEck Pharmaceutical ETF0.05%1,538,88832.20MSep 29, 2026
First TRT Exch-Trd Fd.-First TRT Value Line Dividend Index Fd.0.05%1,714,20135.87MSep 29, 2026
Mercer Funds-Mercer Non-US Core Equity Fund0.02%586,09812.26MJun 29, 2026
GOLDMAN SACHS TRUST-Goldman Sachs Income Builder Fund0.02%494,44210.35MJul 30, 2026
Advertisement